ライフサイエンスコーパス: alternative therapy

1 ow-stage patients that could benefit from an alternative therapy.

2 mptothecin (CPT) has emerged as an effective alternative therapy.

3 symptoms and who often do not have adequate alternative therapy.

4 ulation and lacks accurate information about alternative therapy.

5 ecommendation for chronic transfusions as an alternative therapy.

6 esponse to proton-pump inhibitors often seek alternative therapy.

7 sistant strains, creating an urgent need for alternative therapy.

8 The adverse effects of 5ARIs encourage alternative therapy.

9 hibitor therapy compared to disease-specific alternative therapy.

10 drugs that promote hypokalemia; or using an alternative therapy.

11 tified and offered a detailed evaluation and alternative therapy.

12 urce utilization for HF, and is an effective alternative therapy.

13 ations against antibiotic use and to suggest alternative therapies.

14 ytogenetic features should be considered for alternative therapies.

15 care providers about these complementary and alternative therapies.

16 to use these and many other complementary or alternative therapies.

17 new antibiotic treatments and to research on alternative therapies.

18 ital infections, it is important to research alternative therapies.

19 ication, nonstimulant medication, as well as alternative therapies.

20 djuvant treatment and nonresponders who need alternative therapies.

21 or ablation should be considered as possible alternative therapies.

22 or these problems also use complementary and alternative therapies.

23 zation, and iron overload suggest a need for alternative therapies.

24 population warrants the future use of novel alternative therapies.

25 is a powerful decision aid in choosing among alternative therapies.

26 ies, over-the-counter hormonal products, and alternative therapies.

27 those surveyed reported relying primarily on alternative therapies.

28 t common reasons for using complementary and alternative therapies.

29 proactively discuss the use or avoidance of alternative therapies.

30 nform their patients who may be in search of alternative therapies.

31 e early identification of children requiring alternative therapies.

32 These considerations emphasize the need for alternative therapies.

33 tients are commonly targeted by providers of alternative therapies.

34 bacterium tuberculosis stresses the need for alternative therapies.

35 imatinib exposure, underscores the need for alternative therapies.

36 c-resistant pathogens highlight the need for alternative therapies.

37 k patients who require more intensive and/or alternative therapies.

38 t 25 y, underscoring the urgent need for new alternative therapies.

39 rates of relapse, supporting the need to use alternative therapies.

40 st that these patients may be candidates for alternative therapies.

41 O, there has been a strong effort to develop alternative therapies.

42 idated intermediate end points and effective alternative therapies.

43 tal glomerulosclerosis, its pathogenesis and alternative therapies.

44 peppermint oil are among the most promising alternative therapies.

45 se at 3 to 6 months should be considered for alternative therapies.

46 ms of hazard ratios comparing sorafenib with alternative therapies according to hepatitis C virus (HC

47 ify and characterize the range of unorthodox alternative therapies advertised to patients with a diag

48 It is possible to use these as alternative therapy agents.

49 cators should be used to select patients for alternative therapies and early transplantation.

50 er, who could then consult the prescriber on alternative therapies and implement more intensive monit

51 astration resistance urges the generation of alternative therapies and represents an important health

52 utation is highlighted by the limitations of alternative therapies and the potential for rapid, globa

53 Yet many parents seek alternative therapies, and Hypericum perforatum (St John

54 Most patients proceeded to alternative therapy, and 10 patients (40%) received hema

55 receptor antagonists, steroid resistance and alternative therapy, and new delivery systems.

56 Comparison with alternative therapies appears to be favorable.

57 in cat, and they highlight a possibility for alternative therapies applied at ages thought to be reca

58 As alternative therapies are available for imatinib resista

59 older adults should likely be discouraged if alternative therapies are available.

60 ation is applicable clinically only if valid alternative therapies are available.

61 Alternative therapies are needed to help reduce the need

62 tion-approved neuraminidase (NA) inhibitors, alternative therapies are needed.

63 nergics remain the first-line treatment, but alternative therapies are undergoing clinical trials.

64 onged LBP-targeting leads to resistance, and alternative therapies are urgently required.

65 Complementary and alternative therapies are used more than conventional th

66 es may determine whether close monitoring or alternative therapies are warranted for patients with mi

67 Expenditures for alternative therapy averaged $1,127 per year, compared w

68 Here, we describe development of a low-cost alternative therapy based on intratumoral ethanol inject

69 ng 5 pancreatic cancer treatment modalities (alternative therapy, chemotherapy, clinical trials, radi

70 hageal variceal hemorrhage compared with all alternative therapies combined (relative risk [RR], 0.63

71 heir reasons for nondisclosure of use of 726 alternative therapies, common reasons for nondisclosure

72 Providers of alternative therapies commonly target patients who belie

73 acrolimus is the best primary treatment, but alternative therapies could be instituted in severe case

74 No specific alternative therapy demonstrated a mortality benefit.

75 As a potential alternative therapy, Doxil (Sequus, Menlo Park, CA), a l

76 Use of at least 1 of 16 alternative therapies during the previous year increased

77 antithrombotic for type 2 diabetes and that alternative therapies (e.g. combinations with clopidogre

78 patients, there has been renewed interest in alternative therapies, especially the ketogenic diet.

79 of placebo-controlled trials when effective alternative therapy exists, regardless of the expected e

80 might have potential for the development of alternative therapies for Alzheimer's disease.

81 Alternative therapies for chronic and recurrent dizzines

82 There is a continuing need for innovative, alternative therapies for hepatocellular carcinoma (HCC)

83 transplantation has prompted the search for alternative therapies for intractable liver diseases.

84 s of patients has led to attempts to develop alternative therapies for ischemic disease.

85 ve vaccines have precipitated the search for alternative therapies for malaria.

86 ptimal medical therapy (OMT) are comparable, alternative therapies for many patients with stable angi

87 erapeutic approaches and nonmyelosuppressive alternative therapies for myelodysplasia have been studi

88 tical knowledge of the risks and benefits of alternative therapies for obesity.

89 nutritional supplements have emerged as safe alternative therapies for osteoarthritis (OA), a chronic

90 e collateral development and thereby provide alternative therapies for patients with vascular disease

91 rstand prostate tumorigenesis and to develop alternative therapies for prostate cancer.

92 n reference to cost and efficacy analyses of alternative therapies for sickle cell disease, such as a

93 ness of the health condition and the lack of alternative therapies for some cancer patients.

94 Alternative therapies for Staphylococcus aureus bacterem

95 he past few years, progress has been made in alternative therapies for supporting children and adults

96 e treatment roles and toxicities of WBRT and alternative therapies for the management of brain metast

97 formation on the use of 24 complementary and alternative therapies for the treatment of specific chro

98 every clinician should be aware of evolving alternative therapies for them.

99 Alternative therapies for these patients should be evalu

100 metformin for those predicted to respond and alternative therapies for those predicted to be nonrespo

101 he past few years, progress has been made in alternative therapies for ventilating both children and

102 r 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20

103 ily for 6 weeks and then crossed over to the alternative therapy for an additional 6 weeks.

104 the introduction of parasites as a potential alternative therapy for asthma and other immunological d

105 ation of T-cell costimulation may also be an alternative therapy for children with JIA who are resita

106 of selenium supplementation as additional or alternative therapy for dyslipidemia.

107 Vagal nerve stimulation (VNS) is an alternative therapy for epilepsy and treatment refractor

108 lin A2 may ultimately serve as an efficient, alternative therapy for heart failure.

109 biology indicate that transfer of p53 is an alternative therapy for human gliomas.

110 lements containing botanical ingredients, as alternative therapy for infectious diseases, has been in

111 Transcatheter closure of PFO is an alternative therapy for paradoxical emboli in selected p

112 was shown by this study to be an acceptable alternative therapy for patients with active WG, includi

113 with minimal MAE, it may hold promise as an alternative therapy for patients with CLI and LLC.

114 Currently, there is no proven alternative therapy for patients with familial Mediterra

115 ure by soy isoflavones have implications for alternative therapy for postmenopausal women and patient

116 ntial for development into a safe and potent alternative therapy for prostate cancer patients.

117 ota transplantation (FMT), a safe, effective alternative therapy for recurrent Clostridium difficile

118 B+S is an effective alternative therapy for reducing class I and II anti-HLA

119 est imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS.

120 eatment over time, and there is no effective alternative therapy for these individuals.

121 emic cell survival, KPT-330 may represent an alternative therapy for TKI-refractory Ph(+) leukemias.

122 oral treatments, probiotics, antibiotics and alternative therapies - have developing roles in the tre

123 the widespread adoption of complementary and alternative therapies; however, the prevalence of their

124 the evaluation of different cell models and alternative therapies in a relatively fast way.

125 ed to be as effective or more effective than alternative therapies in improving several common RA dis

126 rials into the efficacy of complementary and alternative therapies in the treatment of depression.

127 ttention has also been focused on the use of alternative therapies in the treatment of HLA-B27-associ

128 Although use of alternative therapies in the United States is widespread

129 d cisplatin therapy, suggesting the need for alternative therapies in this cohort of high-risk patien

130 GODZ shRNA, should be considered a potential alternative therapy in not only HSV-1 but also other con

131 e, and there is no class 1 evidence to guide alternative therapy in patients with breakthrough diseas

132 t ventricular assist device is an acceptable alternative therapy in selected patients who are not can

133 contemporary therapy, should be assigned to alternative therapy in the context of a prospective clin

134 tions, pharmacotherapy, and complementary or alternative therapy) in adults, including pregnant women

135 ith both nonstimulant medications as well as alternative therapies, including diet, iron supplementat

136 Otherwise, it was discontinued and alternative therapies, including extracorporeal membrane

137 Many alternative therapies, including high-dose vitamin C, th

138 ral therapies is reviewed and information on alternative therapies, including nutriceuticals and acup

139 mes are comparable to prospective reports of alternative therapies, including stereotactic body radia

140 bacterial infections in countries where this alternative therapy is approved, many scientists and com

141 ng of fulminant hepatic failure, for whom no alternative therapy is available, may be candidates for

142 In the end, progress on alternative therapies largely depends on our deeper unde

143 Aggressive alternative therapy may not be warranted for RMS patient

144 of children with atopic dermatitis had used alternative therapies, most commonly due to fears of top

145 on or treatment of radiation retinopathy and alternative therapies of uveal melanoma.

146 iated FGF2 gene delivery has potential as an alternative therapy of Alzheimer's disease and possibly

147 luenza strain that is oseltamivir-resistant, alternative therapy options are needed.

148 ntification of patients who may benefit from alternative therapy or who may be spared possible overtr

149 nt-threatening mutations, the model proposes alternative therapies overcoming the resistance.

150 up (GOG) provides strong evidence that a new alternative therapy--paclitaxel (Taxol; Bristol-Myers Sq

151 in the proportion of the population seeking alternative therapies, rather than increased visits per

152 afety profile is acceptable compared with an alternative therapy regarding the time to a clinical eve

153 Development of alternative therapies remains important for patients wit

154 em cells (BM-MSCs) has been considered as an alternative therapy, replacing liver transplantation in

155 nfarction and death and to relieve symptoms, alternative therapy, revascularization to improve surviv

156 nts except fluoxetine in this age group, and alternative therapies should be sought in the first inst

157 The lack of cross-reactivity offers an alternative therapy should the first mAb fail or re-reje

158 Alternative therapies such as cricothyroidotomy and card

159 ment to be modified to include additional or alternative therapy such as bone marrow transplantation.

160 or type and conditioning regimens, or indeed alternative therapies (such as gene therapy) to specific

161 o received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-lin

162 Consequently, there exists a need to develop alternative therapies that more effectively target the c

163 Alternative therapies to consider for future clinical tr

164 n, the intensivist needs to be familiar with alternative therapies to minimize transfusion.

165 evalence, estimated costs, and disclosure of alternative therapies to physicians.

166 resents data on the use of complementary and alternative therapies to treat anxiety and depression in

167 e could be a potential target for developing alternative therapies to treat E. faecalis infections.

168 depression reported using complementary and alternative therapies to treat these conditions during t

169 evere depression also used complementary and alternative therapies to treat these conditions.

170 t or reduced toxicity are actively sought as alternative therapy to a gluten-free diet (GFD) for pati

171 Lapatinib may be an effective alternative therapy to cetuximab in triple wild-type tum

172 ommends mandibular advancement devices as an alternative therapy to continuous positive airway pressu

173 -cells, which is a promising step towards an alternative therapy to insulin.

174 ence supporting the use of ranibizumab as an alternative therapy to PRP for PDR, at least through 2 y

175 he potential use of SA-2 nanoparticles as an alternative therapy to treat PAD.

176 The achievement of these goals makes TMR an alternative therapy to what was formerly the only therap

177 Among treatment modalities, alternative therapy websites exhibited the lowest accura

178 1997 out-of-pocket expenditures relating to alternative therapies were conservatively estimated at $

179 e rates between the 2 survey years; 39.8% of alternative therapies were disclosed to physicians in 19

180 In both surveys alternative therapies were used most frequently for chro

181 l clinical context, patient preferences, and alternative therapies when making transfusion decisions

182 A smaller proportion use 'alternative' therapies, which are typically invasive, bi